Open Access<p>Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring <em>EGFR</em> G719A/V769M Complex Mutation</p>
Author(s) -
Francesca Simionato,
Lorenzo Calvetti,
Marco Cosci,
S. Scarparo,
Giuseppe Aprile
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s280933
Subject(s) - osimertinib , medicine , lung cancer , cancer research , tyrosine kinase , oncology , mutation , epidermal growth factor receptor , lung , tyrosine kinase inhibitor , cancer , receptor , gene , erlotinib , biology , genetics
Complex EGFR mutations are rare in non-small cell lung cancer (NSCLC). Limited clinical evidence is available on the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC harbouring these uncommon EGFR mutations. Here, we reported the case of a complete metabolic response in a patient with advanced NSCLC carrying the uncommon EGFR G719A/V769M complex mutation treated with the first-line osimertinib.